Mirum Pharmaceuticals (NASDAQ: MIRM) insider files to sell 16,515 shares

Rhea-AI Filing Summary

Mirum Pharmaceuticals notice of proposed sale: the filing reports a proposed sale of 16,515 shares of Common Stock, with an aggregate amount shown as $1,529,949.60, dated 03/16/2026. The filing states the securities are Restricted Stock Units vesting under a registered plan on 03/15/2026.

The filing also lists prior open-market sales by Peter Radovich of 2,382, 3,143 and 2,631 shares on 01/22/2026, 01/26/2026 and 02/02/2026, respectively, with corresponding aggregate values shown.

Insights

Insider Transactions Analyst

Form 144 shows a proposed resale of vested RSUs and recent open-market dispositions.

The filing lists a proposed sale of 16,515 shares tied to Restricted Stock Units vesting under a registered plan on 03/15/2026. It also documents three past sales by Peter Radovich totaling 8,156 shares across January–February 2026.

Timing and plan qualifiers are explicit in the excerpt; cash‑flow treatment and whether sales are under a Rule 10b5‑1 plan are not stated in the provided content. Subsequent filings would show consummation details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	16515	1529949.60	60341617	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/15/2026	Restricted Stock Units vesting under registered plan	Issuer			16515	03/15/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Peter Radovich c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	2382	222300.69
Peter Radovich c/o Mirum Pharmaceuticals, Inc. 989 E. Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/26/2026	3143	302331.46
Peter Radovich c/o Mirum Pharmaceuticals, Inc. 989 East Hillsdale Boulevard, Suite 300 Foster City CA 94404	Common Stock	02/02/2026	2631	271791.51

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Mirum Pharmaceuticals' Form 144 report?

The Form 144 reports a proposed sale of 16,515 shares of Common Stock with an aggregate amount of $1,529,949.60, dated 03/16/2026. It ties the shares to RSUs vesting under a registered plan on 03/15/2026.

Who recently sold Mirum (MIRM) shares per the filing?

The filing lists sales by Peter Radovich of 2,382, 3,143 and 2,631 shares on 01/22/2026, 01/26/2026 and 02/02/2026, with aggregate values shown beside each trade in the excerpt.

Are the shares in the Form 144 from compensation or open-market holdings?

The excerpt states the shares are from Restricted Stock Units vesting under a registered plan on 03/15/2026, indicating the source is compensation-related vesting rather than newly authorized issuances or an ATM program.

Does the Form 144 indicate proceeds recipients or trading plan status?

The provided excerpt does not state who receives the proceeds or whether transactions were made pursuant to a Rule 10b5‑1 plan. The filing lists quantities, dates, and aggregate values but omits explicit cash‑flow or trading‑plan language.

How many shares did Radovich sell in the three disclosed trades?

The three disclosed trades by Peter Radovich total 8,156 shares (2,382 + 3,143 + 2,631) across January and February 2026, with separate aggregate dollar amounts provided for each sale in the excerpt.